19 The purpose of this guidance is to assist sponsors in developing drugs for the treatment of low 20 sexual interest, desire, and/or arousal in women.2 Specifically, this guidance addresses the Food 21 and Drug Administration's (FDA's) current thinking regarding the overall clinical development 22 program, wi